Drugs / Parathyroid Hormone-related Protein
Parathyroid Hormone-related Protein
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00177411 | Jul 2005 → Jul 2007 | osteoporosis | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00021827 | Jun 1999 → Dec 2001 | osteoporosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00222872 Comparator | Jul 2005 → Sep 2008 | postmenopausal osteoporosis | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parathyroid Hormone-related Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00222872 ↗ |
| Known as | PTHrP | “Parathyroid hormone-related protein or ''PTHrP''” NCT00021827 ↗ |
| Known as | PTHrP(1-36) | “Group receiving study drug: PTHrP(1-36)” NCT00222872 ↗ |
| Modality | Peptide | “is a peptide secreted by almost all normal tissues and cells” NCT00177411 ↗ |
| Route | Subcutaneous | “administered daily by subcutaneous injection” NCT00021827 ↗ |